|  |  |  |
| --- | --- | --- |
| **Cell Line** | **PBMC Donor**(Number, n) | **Mean EC50 ± SEM(pM)** |
| U-251 MG/EGFRvIII | Human(n = 4) | 2.5 ± 0.3 |
| Cynomolgus Monkey(n = 5) | 6.5 ± 1.7 |
| U-87 MG/EGFRvIII | Human(n = 4) | 2.8 ± 0.2 |
| Cynomolgus Monkey(n = 4) | 16 ± 4 |
| DK-MG | Human(n = 4) | 14.4 ± 1.6 |
| Cynomolgus Monkey(n = 5) | 38.8 ± 9.7 |
| GOS-3/EGFRvIII | Human(n = 4) | 4.6 ± 0.4 |
| Cynomolgus Monkey(n = 5) | 38.5 ± 12.4 |

**Supplementary Table S2. Mean AMG 596 EC50 concentrations required for lysis of EGFRvIII-expressing GBM cells by human and cynomolgus monkey effector cells**

EC50 values of sigmoidal dose response curves shown in **Figure 3** were calculated and averaged. PBMC, peripheral blood mononuclear cells. EGFRvIII, epidermal growth factor receptor variant III.